Abstract:ID 87764 Poster Board 443 Small molecule activators of the mitochondrial matrix protease, caseinolytic protease proteolytic subunit (ClpP), are under investigation for the treatment of aggressive and resilient cancers. Exemplified by the imipridones (ONC201/206, Chimerix), these and related analogs (TR compounds, Madera Therapeutics), disrupt multiple mitochondrial processes required for cancer cell growth. These ClpP agonists induce ClpP-dependent degradation of select matrix proteins, interrupting TCA cycle function, OXPHOS and mitochondrial metabolism, culminating in cancer cell senescence. Our investigation demonstrated that ClpP agonists also cause the degradation of select protein components of the mitochondrial import machinery known as the presequence translocase-associated motor (PAM) complex. Further experimentation demonstrated a concomitant cytosolic accumulation of the senescence-associated mitochondrial matrix protein GRSF1, indicating impairment of import. The goal of this study was to investigate how ClpP activation affects PAM complex proteins and how disruption of this translocase process impacts mitochondrial protein import and function. ClpP-dependent changes in mitochondrial protein abundance were investigated by immunoblotting. Subcellular localization of proteins was determined by manual fractionation of samples into mitochondrial and cytosolic fractions. Log fold changes in PAM complex protein levels were also determined via a global proteomics screen and quantitative peptide analysis using mass spectrometry. All experiments were done in wildtype, triple-negative breast cancer cells (TNBC cells: SUM159, MDA-MB-231) or their corresponding ClpP-knockout derivatives. Following ClpP-agonist treatment of TNBC cells, we detected a ~15 kDa increase in the molecular weight (MW) of the senescence-associated protein GRSF1 by immunoblot. This increase in MW was consistent with retention of the mitochondrial transit sequence (MTS), which is normally cleaved following import into the mitochondrial matrix. Subcellular fractionation revealed accumulation of the higher-weight GRSF1 (65 kDa) in the cytosolic fraction and a depletion of the lower-weight GRSF1 (50 kDa) from the mitochondrial fraction. Parallel proteomics data revealed a ClpP-agonist-dependent decrease in several PAM complex proteins (GRPEL1/2, TIMM44). The decline in GRPEL1 was validated by immunoblot analysis. Finally, the knockdown of specific PAM complex proteins was examined to confirm the effects of PAM complex protein loss on GRSF1 mitochondrial import. Our proteomics data that demonstrated a ClpP-dependent decrease in PAM complex proteins, suggested that mitochondrial protein import would be impaired. Following the fate of GRSF1, we confirmed this hypothesis and highlighted the importance of specific PAM complex proteins in this process. Similar MW shifts were observed with other mitochondrial matrix proteins (ALAS1, GPT2), suggesting broad effects of ClpP agonists on mitochondrial protein import. Previous studies showed that knockdown and inhibition of GRSF1's mitochondrial function was linked to increased senescence. Our data demonstrating ClpP-dependent inhibition of mitochondrial import suggests that this may be another mechanism by which ClpP agonists disrupt GRSF1 function and facilitate the development of senescence in TNBC. NIH GM ROI 138520 Drug-induced ClpP activation leads to PAM complex and mitochondrial matrix GRSF1 degradation

Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment

Targeting POLRMT by IMT1 inhibits colorectal cancer cell growth

Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase

Mitochondria transcription and cancer

Inhibitors of Rho/MRTF/SRF Transcription Pathway Regulate Mitochondrial Function

Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells.

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Abstract 5980: Cancer therapeutic and prevention strategy targeting mutated mitochondria DNA

Small Molecule ClpP-Agonists Block Mitochondrial GRSF1 Entry by Degrading Import Machinery

Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential

Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription.

Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation

Targeting Mitochondria for Cancer Treatment

The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth

Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas

Targeting mitochondrial metabolism for precision medicine in cancer

Investigating Therapies Targeting Druggable Targets of Mitochondria: Exploring the Efficacy for the Treatment of Cancer

Abstract A027: Targeting MYC-induced reprogramming of mitochondrial metabolism in breast cancer